5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide | 869891-72-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
• 英文别名: 5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide；N-piperidinyl-5-(5-bromo-thiophen-2-yl)-1-(2',4'-dichloro phenyl)-4-methyl-1H-pyrazol-3-carboxamide；5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
• CAS: 869891-72-5
• 化学式: C₂₀H₁₉BrCl₂N₄OS
• 分子量: 514.273
• InChiKey: VEWBFNJDWKCEPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide 、 4-苯基-1-丁炔 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 C.I.酸性橙108 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.0h， 以95%的产率得到1-(2,4-dichlorophenyl)-4-methyl-5-(5-(4-phenylbut-1-ynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  Bioisosteric Replacement of the Pyrazole 5-Aryl Moiety of N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A Novel Series of Alkynylthiophenes as Potent and Selective Cannabinoid-1 Receptor Antagonists

  摘要：

  Replacing the conventional pyrazole 5-aryl substituent of 1 (SR141716A) with the 2-thienyl rnoiety appended with ail appropriate alkynyl unit, a novel class of 5-(5-alkynyl-2-thienyl)pyrazole derivatives, behaving as highly potent CB1 receptor antagonists with good CB1/2 selectivity, was discovered, many of which, its typified by compound 18, showed significant weight reduction in diet-indUced obese Mouse model, thus pharmacologically validating that the bioisosteric replacement described above is viable. Also encouraging was the finding that a subtle structural modification of the newly developed series could result in a distinct difference in the intrinsic property, as demonstrated by compounds 12 (NA) and its methylated structural isomers 15 (PA) and 18 (IA). Moreover, current structure-activity relationship Studies revealed that around the pyrazole 5-position of 1, a deep and flat crevice surrounded by a sequence of hydrophobic/aromatic residues as indicated by the CB I-receptor homology model might exist in the binding site.

  DOI：

  10.1021/jm800066v
• 作为产物：
  描述：

  、 1-氨基哌啶 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以73 mg的产率得到5-(5-bromothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  Bioisosteric Replacement of the Pyrazole 5-Aryl Moiety of N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A Novel Series of Alkynylthiophenes as Potent and Selective Cannabinoid-1 Receptor Antagonists

  摘要：

  Replacing the conventional pyrazole 5-aryl substituent of 1 (SR141716A) with the 2-thienyl rnoiety appended with ail appropriate alkynyl unit, a novel class of 5-(5-alkynyl-2-thienyl)pyrazole derivatives, behaving as highly potent CB1 receptor antagonists with good CB1/2 selectivity, was discovered, many of which, its typified by compound 18, showed significant weight reduction in diet-indUced obese Mouse model, thus pharmacologically validating that the bioisosteric replacement described above is viable. Also encouraging was the finding that a subtle structural modification of the newly developed series could result in a distinct difference in the intrinsic property, as demonstrated by compounds 12 (NA) and its methylated structural isomers 15 (PA) and 18 (IA). Moreover, current structure-activity relationship Studies revealed that around the pyrazole 5-position of 1, a deep and flat crevice surrounded by a sequence of hydrophobic/aromatic residues as indicated by the CB I-receptor homology model might exist in the binding site.

  DOI：

  10.1021/jm800066v

文献信息

• SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS
  申请人：Xia Mingde

  公开号：US20070117858A1

  公开（公告）日：2007-05-24

  This invention is directed to a substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulator compound of formula (I): or a form thereof, and methods for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

  这项发明涉及一种式（I）的取代5-杂环芳基-1-苯基-吡唑酮类大麻素调节剂化合物，或其形式，以及用于治疗、改善或预防大麻素受体介导的综合征、疾病或疾病的方法。
• Pharmaceutical compounds
  申请人：Lazzari Paolo

  公开号：US20050261281A1

  公开（公告）日：2005-11-24

  Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors: wherein: R is a group selected from: C 1 -C 10 alkyl; aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; A is a group selected from the following: an ether group of formula —(CH 2 )—O—(CH 2 ) v —R″ wherein v is equal to 1 or 2; R″ is as defined in the present application; a ketone group of formula —C(O)-Z′, wherein Z′ is as defined in the present application; a substituent having an hydroxyl function of formula —CH(OH)-Z′, Z′ being as defined in the present application; Description of the industrial invention in the name of: NEUROSCIENZE S.c. a r.l., of Italian nationality, with head office in Cagliari, via Palabanda 9.

  以下式子（I）的吡唑衍生物具有对大麻素受体CB1和/或CB2的亲和力：其中：R是以下组中选择的一组：C1-C10烷基；芳基，芳基烷基或芳基烯基，未取代或具有一个到四个取代基，相互相同或不同；A是以下组中选择的一组：化学式为—（CH2）-O-（CH2）v-R″的醚基，其中v等于1或2；R″如本申请所定义；化学式为—C（O）-Z′的酮基，其中Z′如本申请所定义；具有羟基功能的取代基，化学式为—CH（OH）-Z′，其中Z′如本申请所定义；该工业发明的描述以NEUROSCIENZE S.c. a r.l.的名义进行，该公司是意大利国籍，总部位于卡利亚里，Palabanda 9号。
• Modulating the affinity and signaling bias of cannabinoid receptor 1 antagonists
  作者：Wen-Chi Hsiao、Kun-Yi Hsin、Zhong-Wei Wu、Jen-Shin Song、Yen-Nan Yeh、Yan-Fu Chen、Chia-Hua Tsai、Pei-Hsuan Chen、Kak-Shan Shia、Chun-Ping Chang、Ming-Shiu Hung

  DOI：10.1016/j.bioorg.2022.106236

  日期：2023.1

  metabolic disorders. Numerous CB1 antagonists have been developed, but their functional selectivities and bias towards G protein or β-arrestin signaling have not been systemically characterized. In this study, we analyzed the binding affinities and downstream signaling of two series of pyrazole derivatives bearing 1-aminopiperidine (Series I) or 4-aminothiomorpholine 1,1-dioxide (Series II) moieties, as

  大麻素受体 1 (CB1) 是一种 G 蛋白偶联受体，是代谢紊乱的治疗靶点。已经开发了许多 CB1 拮抗剂，但它们的功能选择性和对 G 蛋白或 β-arrestin 信号传导的偏向尚未得到系统表征。在这项研究中，我们分析了带有 1-氨基哌啶（系列 I）或 4-氨基硫代吗啉 1,1-二氧化物（系列 II）部分的两个系列吡唑衍生物以及众所周知的 CB1 拮抗剂的结合亲和力和下游信号传导利莫那班和他拉那班。对系列 I 和 II 衍生物的结果分析表明，对其官能团进行了微小的结构修饰，尤其是加入了 1-氨基哌啶或 4-氨基硫代吗啉 1，1-二氧化物基序可以深刻影响它们对 G 蛋白或 β-抑制蛋白信号的偏向，并且它们的结合亲和力和功能活性可以分离。对接和分子动力学模拟表明，I 系列和 II 系列拮抗剂的结合模式主要不同在于，I 系列拮抗剂与受体形成额外的氢键，而 II 系列拮抗剂形成水桥。
• PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS
  申请人：NEUROSCIENZE PHARMANESS S.C. a R.L.

  公开号：EP1602656A1

  公开（公告）日：2005-12-07

  Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors:    wherein: R is a group selected from: C1-C10 alkyl; aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; A is a group selected from the following: an ether group of formula -(CH2)-O-(CH2)v-R" wherein    - v is equal to 1 or 2;    - R" is as defined in the present application; a ketone group of formula -C(O)-Z', wherein Z' is as defined in the present application; a substituent having an hydroxyl function of formula -CH(OH)-Z', Z' being as defined in the present application; an amide substituent of formula -C(O)-NH-T', T' being as defined in the present application; B is a group as defined in the present application; D is an heteroaryl optionally substituted.

  对大麻素能 CB1 和/或 CB2 受体具有亲和力的下式 (I) 吡唑衍生物： 其中 R 是选自以下各项的基团 C1-C10 烷基 芳基、芳烷基或芳烯基，未被取代或具有一至四个相互等同或不同的取代基； A 是选自以下的基团 式中的醚基-(CH2)-O-(CH2)v-R" 其中 - v 等于 1 或 2； - R "如本申请中所定义； 式-C(O)-Z'的酮基，其中 Z'如本申请中所定义； 式-CH(OH)-Z'的具有羟基官能团的取代基，其中 Z'定义如本申请所 述； 式-C(O)-NH-T'的酰胺取代基，T'如本申请中所定义； B 是本申请中所定义的基团； D 是任选取代的杂芳基。
• Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a cb1 receptor antagonist with in vivo antiobesity effect
  作者：Brijesh Kumar Srivastava、Rina Soni、Jayendra Z. Patel、Amit Joharapurkar、Nisha Sadhwani、Samadhan Kshirsagar、Bhupendra Mishra、Vijay Takale、Sunil Gupta、Purvi Pandya、Prashant Kapadnis、Manish Solanki、Harilal Patel、Prasenjit Mitra、Mukul R. Jain、Pankaj R. Patel

  DOI：10.1016/j.bmcl.2009.03.046

  日期：2009.5

  A few thienyl substituted pyrazole derivatives were synthesized to aid in the characterization of the cannabinoid receptor antagonist and also to serve as potentially useful antiobesity agent. Structural requirements for selective CB1 receptor antagonistic activity of 5-thienyl pyrazole derivatives included the structural similarity with potent, specific antagonist rimonabant 1. Compound 3 has been identified as a hair growth stimulator and an antiobesity agent in animal models. (C) 2009 Elsevier Ltd. All rights reserved.